Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats

Imagem de Miniatura
Arquivos
art_JORGETTI_Pamidronate_for_the_treatment_of_osteoporosis_secondary_to_2012.PDF (1.26 MB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2012
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC BRAS DIVULG CIENTIFICA
Autores
PEREIRA, F. A.
MATTAR, R.
FACINCANI, I.
DEFINO, H. L. A.
RAMALHO, L. N. Z.
VOLPON, J. B.
Citação
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, v.45, n.12, p.1255-1261, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Osteoporosis is a major complication of chronic cholestatic liver disease (CCLD). We evaluated the efficacy of using disodium pamidronate (1.0 mg/kg body weight) for the prevention (Pr) or treatment (Tr) of cholestasis-induced osteoporosis in male Wistar rats: sham-operated (Sham = 12); bile duct-ligated (Bi = 15); bile duct-ligated animals previously treated with pamidronate before and 1 month after surgery (Pr = 9); bile duct-ligated animals treated with pamidronate 1 month after surgery (Tr = 9). Rats were sacrificed 8 weeks after surgery. Immunohistochemical expression of IGF-I and GH receptor was determined in the proximal growth plate cartilage of the left tibia. Histomorphometric analysis was performed in the right tibia and the right femur was used for biomechanical analysis. Bone material volume over tissue volume (BV/TV) was significantly affected by CCLD (Sham = 18.1 +/- 3.2 vs Bi = 10.6 +/- 2.2%) and pamidronate successfully increased bone volume. However, pamidronate administered in a preventive regimen presented no additional benefit on bone volume compared to secondary treatment (BV/TV: Pr = 39.4 +/- 12.0; Tr = 41.2 +/- 12.7%). Moreover, the force on the momentum of fracture was significantly reduced in Pr rats (Sham = 116.6 +/- 23.0; Bi = 94.6 +/- 33.8; Pr = 82.9 +/- 22.8; Tr = 92.5 +/- 29.5 N; P < 0.05, Sham vs Pr). Thus, CCLD had a significant impact on bone histomorphometric parameters and pamidronate was highly effective in increasing bone mass in CCLD; however, preventive therapy with pamidronate has no advantage regarding bone fragility.
Palavras-chave
Osteoporosis pathogenesis, Growth factors, Biomechanics, Animal models, Pamidronate
URI
https://observatorio.fm.usp.br/handle/OPI/1303
Referências
  1. Bachrach LK, 2009, J CLIN ENDOCR METAB, V94, P400, DOI 10.1210/jc.2008-1531
  2. Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
  3. Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2
  4. Burr DB, 2002, BONE, V30, P2, DOI 10.1016/S8756-3282(01)00619-6
  5. CAPRA F, 1991, ITAL J GASTROENTEROL, V23, P124
  6. CHAPPARD D, 1989, PATHOL RES PRACT, V184, P480
  7. Chen CC, 1996, J GASTROEN HEPATOL, V11, P417, DOI 10.1111/j.1440-1746.1996.tb00284.x
  8. Courtland HW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014762
  9. Crawford BAL, 2003, OSTEOPOROSIS INT, V14, P987, DOI 10.1007/s00198-003-1495-z
  10. Elis S, 2010, J BONE MINER RES, V25, P1257, DOI 10.1002/jbmr.20
  11. Eriksen EF, 2002, BONE, V31, P620, DOI 10.1016/S8756-3282(02)00869-4
  12. Gasser Rudolf W, 2008, Wien Med Wochenschr, V158, P553, DOI 10.1007/s10354-008-0594-z
  13. Goral V, 2010, WORLD J GASTROENTERO, V16, P1639, DOI 10.3748/wjg.v16.i13.1639
  14. Grossman JM, 2010, ARTHRIT CARE RES, V62, P1515, DOI 10.1002/acr.20295
  15. GUANABENS N, 1990, AM J GASTROENTEROL, V85, P1356
  16. Horton JA, 2008, ANAT REC, V291, P283, DOI 10.1002/ar.20650
  17. JORGEHERNANDEZ JA, 1988, DIGEST DIS SCI, V33, P1089, DOI 10.1007/BF01535783
  18. Kippo K, 1998, J BONE MINER RES, V13, P287, DOI 10.1359/jbmr.1998.13.2.287
  19. Kippo K, 1997, CALCIFIED TISSUE INT, V61, P151, DOI 10.1007/s002239900314
  20. Li J, 2001, CALCIFIED TISSUE INT, V69, P281, DOI 10.1007/s002230010036
  21. Lopez-Larramona German, 2011, World J Hepatol, V3, P300, DOI 10.4254/wjh.v3.i12.300
  22. Miller PD, 2008, BEST PRACT RES CL EN, V22, P849, DOI 10.1016/j.beem.2008.07.004
  23. Monegal A, 1997, CALCIFIED TISSUE INT, V60, P148
  24. Okuda S, 2001, SPINE, V26, P2421, DOI 10.1097/00007632-200111150-00005
  25. Olson LE, 2011, CALCIFIED TISSUE INT, V88, P1, DOI 10.1007/s00223-010-9436-2
  26. PARFITT AM, 1987, J BONE MINER RES, V2, P595
  27. PENG Z, 1994, BONE, V15, P523, DOI 10.1016/8756-3282(94)90276-3
  28. Pereira FA, 2009, CALCIFIED TISSUE INT, V85, P75, DOI 10.1007/s00223-009-9249-3
  29. Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
  30. Rosen CJ, 2012, NAT MED, V18, P202, DOI 10.1038/nm.2630
  31. Taveira ATA, 2010, BRAZ J MED BIOL RES, V43, P1127, DOI 10.1590/S0100-879X2010007500118
  32. Taveira ATA, 2007, CLIN ENDOCRINOL, V66, P518, DOI 10.1111/j.1365-2265.2007.02765.x
  33. Thornton J, 2008, HEALTH TECHNOL ASSES, V12, P1
  34. TOOLAN BC, 1992, J BONE MINER RES, V7, P1399
  35. Turner A. Simon, 2001, European Cells & Materials, V1, P66
  36. Yang KY, 2007, YONSEI MED J, V48, P653, DOI 10.3349/ymj.2007.48.4.653

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/16